{"id":"rifaximine","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Fever","Hemorrhagic diarrhea","Pseudomembranous enterocolitis"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Targaxan"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Nuclear receptor subfamily 1 group I member 2, Bacterial DNA-directed RNA polymerase"},"_scrapedAt":"2026-03-28T03:46:06.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Diarrhea due to E. Coli","diseaseId":"diarrhea-due-to-e.-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hepatic encephalopathy","diseaseId":"hepatic-encephalopathy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Irritable bowel syndrome with diarrhea","diseaseId":"irritable-bowel-syndrome-with-diarrhea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07285785","phase":"PHASE4","title":"Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2026-02-11","conditions":"Diarrhea, Gastroenteritis, Bacterial Infection","enrollment":54},{"nctId":"NCT05159427","phase":"PHASE1","title":"Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2022-03-15","conditions":"Human Gastrointestinal Physiology Data","enrollment":40},{"nctId":"NCT07454408","phase":"PHASE1, PHASE2","title":"Evaluation of the Outcome of Fecal Microbiota Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Air Force Military Medical University, China","startDate":"2026-03-07","conditions":"Hepatic Encephalopathy, Fecal Microbiota Transplantation, TIPS","enrollment":40},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT07426705","phase":"PHASE4","title":"Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji","startDate":"2026-02-15","conditions":"Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS","enrollment":100},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT07381257","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin-α in Treating MASLD","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-01-15","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease","enrollment":60},{"nctId":"NCT07209371","phase":"PHASE2","title":"Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-01-22","conditions":"IgA Monoclonal Gammopathy of Undetermined Significance","enrollment":50},{"nctId":"NCT03729271","phase":"PHASE4","title":"Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2020-01-09","conditions":"Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea","enrollment":148},{"nctId":"NCT04244877","phase":"PHASE3","title":"Rifaximin's Effect on Covert Hepatic Encephalopathy With SIBO and Gastrointestinal Dysmotility","status":"WITHDRAWN","sponsor":"MetroHealth Medical Center","startDate":"2021-09-15","conditions":"Cirrhosis, Liver, Minimal Hepatic Encephalopathy, Small Intestinal Bacterial Overgrowth","enrollment":""},{"nctId":"NCT05253287","phase":"PHASE2, PHASE3","title":"Growth Hormone in Decompensated Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-02-01","conditions":"Liver Cirrhosis, Fibrosis, End Stage Liver Disease","enrollment":96},{"nctId":"NCT06223685","phase":"NA","title":"The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin","status":"COMPLETED","sponsor":"Pomeranian Medical University Szczecin","startDate":"2023-04-01","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth, SIBO","enrollment":129},{"nctId":"NCT06727422","phase":"PHASE2","title":"Efficacy of Rifaximin With NAC in IBS-D","status":"NOT_YET_RECRUITING","sponsor":"Mark Pimentel, MD","startDate":"2025-12-15","conditions":"IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)","enrollment":225},{"nctId":"NCT04254549","phase":"PHASE2","title":"Rifaximin in Patients With Diabetic Gastroparesis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2019-06-14","conditions":"Crohn Disease, Diabetic Gastroparesis","enrollment":5},{"nctId":"NCT07203846","phase":"PHASE4","title":"Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","status":"NOT_YET_RECRUITING","sponsor":"Collegium Medicum w Bydgoszczy","startDate":"2026-01-01","conditions":"ACS - Acute Coronary Syndrome, Ticagrelor, Microbiota","enrollment":50},{"nctId":"NCT07185932","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Rifaximin in Treating MAFLD","status":"RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2024-08-10","conditions":"Metabolic-associated Fatty Liver Disease","enrollment":40},{"nctId":"NCT06443502","phase":"PHASE3","title":"A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-11-19","conditions":"Pouchitis","enrollment":30},{"nctId":"NCT07180615","phase":"PHASE4","title":"Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery","status":"NOT_YET_RECRUITING","sponsor":"Universität Luzern","startDate":"2026-06-01","conditions":"Surgical Site Infection, Colon Surgery, Surgical Site Infections","enrollment":458},{"nctId":"NCT04249622","phase":"PHASE2","title":"Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2020-09-18","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8","enrollment":20},{"nctId":"NCT05297448","phase":"PHASE3","title":"Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-08-03","conditions":"Hepatic Encephalopathy","enrollment":466},{"nctId":"NCT03575195","phase":"PHASE1, PHASE2","title":"Microbiota Intervention to Change the Response of Parkinson's Disease","status":"SUSPENDED","sponsor":"University of California, San Francisco","startDate":"2019-07-15","conditions":"Parkinson Disease","enrollment":86},{"nctId":"NCT05754996","phase":"PHASE3","title":"Efficacy and Safety of Nifuroxazide in the Treatment of Hepatic Encephalopathy in Egyptian Patients With Liver Cirrhosis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-03-12","conditions":"Hepatic Encephalopathy","enrollment":80},{"nctId":"NCT06483737","phase":"NA","title":"Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":"Overt Hepatic Encephalopathy","enrollment":174},{"nctId":"NCT06058572","phase":"PHASE2","title":"Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-08-02","conditions":"Acute Leukemia","enrollment":166},{"nctId":"NCT05071716","phase":"PHASE3","title":"Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-04-07","conditions":"Hepatic Encephalopathy","enrollment":524},{"nctId":"NCT05453916","phase":"PHASE1, PHASE2","title":"Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2022-07-01","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":""},{"nctId":"NCT06312683","phase":"PHASE4","title":"Rifaximin for the Secondary Prevention of Recurrent Pouchitis","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-07-01","conditions":"Pouchitis","enrollment":16},{"nctId":"NCT05408910","phase":"PHASE2, PHASE3","title":"Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2025-07","conditions":"Cystic Fibrosis, Abdominal Pain, Small Bowel Disease","enrollment":""},{"nctId":"NCT07037394","phase":"PHASE4","title":"A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy.","status":"COMPLETED","sponsor":"Qurratul Ain Jamil","startDate":"2024-12-02","conditions":"Overt Hepatic Encephalopathy","enrollment":252},{"nctId":"NCT06298409","phase":"PHASE1","title":"Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®","status":"RECRUITING","sponsor":"Envivo Bio Inc","startDate":"2024-02-15","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":34},{"nctId":"NCT06538077","phase":"PHASE4","title":"BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-02-01","conditions":"Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy","enrollment":336},{"nctId":"NCT05677282","phase":"PHASE4","title":"Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2022-10-28","conditions":"Diarrhoea;Acute, Diarrhea Travelers","enrollment":150},{"nctId":"NCT06852274","phase":"NA","title":"Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study","status":"COMPLETED","sponsor":"Dr. Amjad Khan","startDate":"2023-03-01","conditions":"Diverticular Diseases, Gastro-Intestinal Disorder","enrollment":70},{"nctId":"NCT06772064","phase":"NA","title":"Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.","status":"RECRUITING","sponsor":"Xiuli Zuo","startDate":"2025-04-15","conditions":"SIBO","enrollment":115},{"nctId":"NCT03219528","phase":"PHASE4","title":"A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2018-02-13","conditions":"Irritable Bowel Syndrome","enrollment":74},{"nctId":"NCT05204641","phase":"PHASE2","title":"Effect of Fecal Microbiota Transfer on Progression of Parkinson Disease","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2022-01-04","conditions":"Parkinson Disease","enrollment":59},{"nctId":"NCT03820817","phase":"PHASE1","title":"Rifaximin in Patients With Monoclonal Gammopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-05-15","conditions":"IgA Monoclonal Gammopathy, IgG Monoclonal Gammopathy, IgM Monoclonal Gammopathy","enrollment":50},{"nctId":"NCT03069131","phase":"PHASE3","title":"Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2018-06-05","conditions":"Cirrhosis, Ascites, Peritonitis","enrollment":160},{"nctId":"NCT06743464","phase":"NA","title":"Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-12-01","conditions":"Chronic Liver Disease","enrollment":100},{"nctId":"NCT05604274","phase":"","title":"Longitudinal Monitoring of Stool Characteristics","status":"COMPLETED","sponsor":"Hunter Holmes Mcguire Veteran Affairs Medical Center","startDate":"2022-10-28","conditions":"Cirrhosis, Liver","enrollment":60},{"nctId":"NCT06808009","phase":"NA","title":"Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":90},{"nctId":"NCT04073290","phase":"PHASE4","title":"Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2020-01-21","conditions":"Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension","enrollment":238},{"nctId":"NCT06783153","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-01-20","conditions":"Radiotherapy Induced Diarrhea, Acute Radiation Enteritis, Prostate Cancer","enrollment":80},{"nctId":"NCT06718686","phase":"PHASE1, PHASE2","title":"Rifaximin SSD in Dementia Trial","status":"RECRUITING","sponsor":"Jasmohan Bajaj","startDate":"2024-12-30","conditions":"Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease","enrollment":20},{"nctId":"NCT05587036","phase":"PHASE2, PHASE3","title":"Effects of Rifaximin on Gut Microbiota and Emotion","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-02-02","conditions":"Healthy Volunteers, Stress, Fear","enrollment":60},{"nctId":"NCT06652087","phase":"NA","title":"Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction","status":"RECRUITING","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2024-09-02","conditions":"Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction","enrollment":40},{"nctId":"NCT06630572","phase":"PHASE4","title":"Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes","status":"TERMINATED","sponsor":"University of Roma La Sapienza","startDate":"2021-04-03","conditions":"Liver Cirrhosis, Coagulation Disorder, Platelet Disorder","enrollment":20},{"nctId":"NCT02193763","phase":"NA","title":"Bedside Ultrasound Assisted Pediatric Lumbar Puncture","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2009-08","conditions":"Infant/ Neonate Lumbar Puncture","enrollment":""},{"nctId":"NCT05098028","phase":"PHASE2","title":"Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2022-03-22","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT06518850","phase":"PHASE1, PHASE2","title":"Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-08-01","conditions":"Small Intestine Bacterial Overgrowth","enrollment":30},{"nctId":"NCT01345175","phase":"PHASE3","title":"Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-04-26","conditions":"Rectal Cancer","enrollment":69},{"nctId":"NCT04199910","phase":"","title":"4beta-hydroxycholesterol in Cirrhosis","status":"SUSPENDED","sponsor":"University of Oulu","startDate":"2019-12-01","conditions":"Cirrhosis, Liver","enrollment":120},{"nctId":"NCT05150587","phase":"PHASE2","title":"Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea","status":"COMPLETED","sponsor":"Alfasigma S.p.A.","startDate":"2021-10-05","conditions":"Papulopustular Rosacea","enrollment":216},{"nctId":"NCT06368895","phase":"PHASE1","title":"Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-04-07","conditions":"Hepatic Encephalopathy, Dysbiosis","enrollment":60},{"nctId":"NCT06328088","phase":"","title":"Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study","status":"RECRUITING","sponsor":"Sir Ganga Ram Hospital","startDate":"2024-02-16","conditions":"Hepatic Encephalopathy","enrollment":40},{"nctId":"NCT02470780","phase":"PHASE2, PHASE3","title":"Treating Bacterial Overgrowth in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2015-12","conditions":"Parkinson's Disease, Small Intestinal Bacterial Overgrowth","enrollment":4},{"nctId":"NCT06234046","phase":"PHASE3","title":"Rifaximin as a Prophylaxis of Spontaneous Bacterial Peritonitis in Comparison With Ciprofloxacin","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-05-28","conditions":"Spontaneous Bacterial Peritonitis","enrollment":80},{"nctId":"NCT04910815","phase":"NA","title":"Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.","status":"UNKNOWN","sponsor":"Atmo Biosciences Pty Ltd","startDate":"2021-07-14","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":150},{"nctId":"NCT06199843","phase":"NA","title":"Efficacy of Rifaximin vs Norfloxacin for Secondary Prophylaxis of SBP (NORRIF Trial)","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-01-05","conditions":"Spontaneous Bacterial Peritonitis","enrollment":280},{"nctId":"NCT01846663","phase":"PHASE4","title":"Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2013-04-03","conditions":"Hepatic Encephalopathy","enrollment":6},{"nctId":"NCT03818672","phase":"PHASE4","title":"Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects","status":"TERMINATED","sponsor":"Bausch Health Americas, Inc.","startDate":"2019-01-29","conditions":"Severe Hepatic Impairment","enrollment":5},{"nctId":"NCT04592289","phase":"NA","title":"Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Rectal Resections for Cancer Versus MBP Alone","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2020-10-30","conditions":"Rectal Cancer","enrollment":622},{"nctId":"NCT05502913","phase":"PHASE2","title":"Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer","status":"RECRUITING","sponsor":"Soroka University Medical Center","startDate":"2023-09-01","conditions":"Metastatic Lung Cancer","enrollment":80},{"nctId":"NCT06020365","phase":"NA","title":"Investigation of Fecal Microbiota Transplant in Chronic Intestinal Pseudo-obstruction Patients","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2018-01-01","conditions":"Intestinal Pseudo-Obstruction, Fecal Microbiota Transplantation","enrollment":10},{"nctId":"NCT02620007","phase":"PHASE2","title":"Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Crohn Disease, Adherent-invasive E. Coli","enrollment":24},{"nctId":"NCT05863364","phase":"NA","title":"Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Xin Zeng","startDate":"2023-08-18","conditions":"Decompensated Cirrhosis","enrollment":150},{"nctId":"NCT05867550","phase":"PHASE4","title":"To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea","status":"COMPLETED","sponsor":"Bahria University","startDate":"2023-01-03","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":162},{"nctId":"NCT03780673","phase":"PHASE2, PHASE3","title":"Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development","status":"COMPLETED","sponsor":"Judit Pich","startDate":"2019-01-03","conditions":"Liver Cirrhoses","enrollment":254},{"nctId":"NCT04841980","phase":"PHASE4","title":"Rifaximin Therapy vs Low FODMAP Diet In IBS","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2021-04-22","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth","enrollment":100},{"nctId":"NCT03420144","phase":"PHASE2, PHASE3","title":"Growth Hormone Therapy in Liver Cirrhosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2018-01-15","conditions":"Cirrhosis, Liver","enrollment":76},{"nctId":"NCT03515044","phase":"PHASE2","title":"Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-09-13","conditions":"Overt Hepatic Encephalopathy","enrollment":71},{"nctId":"NCT05546892","phase":"NA","title":"Short-term Outcomes of Full Bowel Preparation (MBP+OA) for Colon Cancer Resections Versus no Bowel Preparation","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2023-02-10","conditions":"Colon Cancer","enrollment":586},{"nctId":"NCT04557215","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Rifaximin With NAC in IBS-D","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-11-13","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":45},{"nctId":"NCT05786859","phase":"EARLY_PHASE1","title":"The Efficacy and Safety of Rifaximin Treatment","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-09","conditions":"Liver Failure, Acute on Chronic, Hepatic Encephalopathy, HBV","enrollment":124},{"nctId":"NCT02498301","phase":"NA","title":"Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2015-11-10","conditions":"Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis","enrollment":449},{"nctId":"NCT04775329","phase":"PHASE2, PHASE3","title":"Primary Prophylaxis for Spontaneous Bacterial Peritonitis","status":"TERMINATED","sponsor":"Changi General Hospital","startDate":"2020-11-01","conditions":"Decompensated Cirrhosis, Small Bowel Bacterial Overgrowth Syndrome","enrollment":2},{"nctId":"NCT05621005","phase":"PHASE2","title":"Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients","status":"COMPLETED","sponsor":"Samar Atef Sebaweh Mohammed","startDate":"2019-03-01","conditions":"Ascites Infection","enrollment":104},{"nctId":"NCT04316806","phase":"NA","title":"Effect of a Probiotic Formula on Reducing SIBO in IBS Patients","status":"TERMINATED","sponsor":"AB Biotics, SA","startDate":"2020-11-20","conditions":"Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth","enrollment":8},{"nctId":"NCT03462966","phase":"PHASE2","title":"Rifaximin on Visceral Hypersensitivity","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-07-01","conditions":"Visceral Hypersensitivity, Irritable Bowel Syndrome","enrollment":4},{"nctId":"NCT01137955","phase":"NA","title":"Rifaximin for the Treatment of Persistent Symptoms in Patients With Celiac Disease","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":"Celiac Disease","enrollment":50},{"nctId":"NCT03557788","phase":"PHASE4","title":"Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2018-05-07","conditions":"Irritable Bowel Syndrome With Diarrhea","enrollment":33},{"nctId":"NCT05083572","phase":"PHASE4","title":"Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers","status":"UNKNOWN","sponsor":"Changi General Hospital","startDate":"2021-03-10","conditions":"Dysbiosis","enrollment":32},{"nctId":"NCT02439307","phase":"NA","title":"Effycacy of Rifaximin on Reverse Minimal Hepatic Encephalopathy and Elimation Small Intestinal Bacterial","status":"TERMINATED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-28","conditions":"Small Intestinal Bacterial Overgrowth, Liver Cirrhosis","enrollment":11},{"nctId":"NCT00748904","phase":"PHASE4","title":"Rifaximin Versus Lactulose in Renal Failure","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-06","conditions":"Liver Cirrhosis, Renal Failure","enrollment":""},{"nctId":"NCT02651740","phase":"PHASE2, PHASE3","title":"Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2016-04","conditions":"Irritable Bowel Syndrome","enrollment":10},{"nctId":"NCT03856359","phase":"PHASE2","title":"Trial of Rifaximin in Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-04-09","conditions":"Alzheimer's Disease","enrollment":10},{"nctId":"NCT00603616","phase":"PHASE2","title":"Induction of Clinical Response Using Rifaximin in Crohn's Disease","status":"COMPLETED","sponsor":"Scott Lee","startDate":"2008-11","conditions":"Crohn's Disease","enrollment":36},{"nctId":"NCT02342639","phase":"PHASE4","title":"Rifaximin Therapy in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Jason Stubbs, MD","startDate":"2015-06","conditions":"Chronic Kidney Disease","enrollment":38},{"nctId":"NCT02555293","phase":"PHASE2","title":"Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2016-02","conditions":"Malignant Liver Disease, Major Liver Resection","enrollment":96},{"nctId":"NCT03469050","phase":"PHASE2, PHASE3","title":"Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2018-07-02","conditions":"Diverticulitis","enrollment":193},{"nctId":"NCT01670149","phase":"PHASE4","title":"Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2012-12","conditions":"Clostridium Difficile Infection","enrollment":151},{"nctId":"NCT03529825","phase":"EARLY_PHASE1","title":"Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-07-18","conditions":"Microbial Colonization","enrollment":26},{"nctId":"NCT02272868","phase":"PHASE1, PHASE2","title":"Fecal Microbial Transplant in Pediatric Crohn's Disease","status":"TERMINATED","sponsor":"Seattle Children's Hospital","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":7},{"nctId":"NCT03537157","phase":"PHASE2","title":"A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2017-11-16","conditions":"Crohn Disease","enrollment":43},{"nctId":"NCT04128462","phase":"PHASE3","title":"MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function","status":"WITHDRAWN","sponsor":"Mallinckrodt","startDate":"2021-11","conditions":"Hepatic Encephalopathy","enrollment":""},{"nctId":"NCT04003181","phase":"NA","title":"The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2017-09-28","conditions":"Colon Adenocarcinoma, Diarrhea","enrollment":64},{"nctId":"NCT03613545","phase":"PHASE2, PHASE3","title":"Fecal Microbiota Transplantation for Irritable Bowel Syndrome","status":"RECRUITING","sponsor":"Guangzhou First People's Hospital","startDate":"2018-08-10","conditions":"Irritable Bowel Syndrome, Fecal Microbiota Transplantation","enrollment":120},{"nctId":"NCT03712280","phase":"PHASE2","title":"MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)","status":"COMPLETED","sponsor":"Mallinckrodt","startDate":"2018-12-01","conditions":"Hepatic Cirrhosis, Hepatic Encephalopathy (HE)","enrollment":50},{"nctId":"NCT03077217","phase":"PHASE4","title":"Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Shanghai Changzheng Hospital","startDate":"2017-05-01","conditions":"Covert Hepatic Encephalopathy","enrollment":40},{"nctId":"NCT04118699","phase":"PHASE2","title":"Efficacy and Safety of Rifaximin for Patients With Chronic Intestinal Pseudo-obstruction: a Phase 2 Trial","status":"UNKNOWN","sponsor":"Yokohama City University","startDate":"2019-12-25","conditions":"Chronic Intestinal Pseudo-obstruction","enrollment":12}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"DIARRHOEA"},{"count":5,"reaction":"HEPATIC FAILURE"},{"count":4,"reaction":"DRUG RESISTANCE"},{"count":4,"reaction":"ENCEPHALOPATHY"},{"count":4,"reaction":"HEPATIC ENCEPHALOPATHY"},{"count":3,"reaction":"GLOMERULAR FILTRATION RATE DECREASED"},{"count":3,"reaction":"HEPATITIS C"},{"count":3,"reaction":"PYREXIA"},{"count":3,"reaction":"SEPTIC SHOCK"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Rifaximine","genericName":"Rifaximine","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifaximin is a non-absorbable, broad-spectrum antibiotic that inhibits bacterial DNA-directed RNA polymerase, a bacterial enzyme involved in RNA synthesis. It is primarily used to treat non-infectious gastrointestinal diseases, including irritable bowel syndrome, and has been licensed in over 30 countries for various conditions such as diverticular disease, bloating, and functional bowel disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}